Cargando…
Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma
The B-cell receptor (BCR) signaling pathway has gained significant attention as a therapeutic target in B-cell malignancies. Recently, several drugs that target the BCR signaling pathway, especially the Btk inhibitor ibrutinib, have demonstrated notable therapeutic effects in relapsed/refractory pat...
Autores principales: | Ding, Ning, Li, Xitao, Shi, Yunfei, Ping, Lingyan, Wu, Lina, Fu, Kai, Feng, Lixia, Zheng, Xiaohui, Song, Yuqin, Pan, Zhengying, Zhu, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558140/ https://www.ncbi.nlm.nih.gov/pubmed/25944695 |
Ejemplares similares
-
Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function
por: Tullemans, Bibian M.E., et al.
Publicado: (2021) -
Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017) -
ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
por: Ghoshdastidar, Krishnarup, et al.
Publicado: (2020) -
BTK blocks the inhibitory effects of MDM2 on p53 activity
por: Rada, Miran, et al.
Publicado: (2017) -
Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA
por: Meng, Amy, et al.
Publicado: (2021)